Eli Lilly and Company Share Price

Equities

LLY

US5324571083

Pharmaceuticals

Real-time Estimate Cboe BZX 15:02:04 29/05/2024 BST 5-day change 1st Jan Change
804.9 USD -0.37% Intraday chart for Eli Lilly and Company +0.13% +37.92%
Sales 2024 * 43B 3,370B Sales 2025 * 52.61B 4,123B Capitalization 727B 57,002B
Net income 2024 * 11.93B 935B Net income 2025 * 16.55B 1,297B EV / Sales 2024 * 17.4 x
Net Debt 2024 * 19.98B 1,566B Net Debt 2025 * 15.29B 1,198B EV / Sales 2025 * 14.1 x
P/E ratio 2024 *
60.4 x
P/E ratio 2025 *
43.5 x
Employees 43,000
Yield 2024 *
0.64%
Yield 2025 *
0.74%
Free-Float 99.8%
More Fundamentals * Assessed data
Dynamic Chart
1 day-0.08%
1 week+0.58%
Current month+3.43%
1 month+10.14%
3 months+6.63%
6 months+36.56%
Current year+38.59%
More quotes
1 week
788.25
Extreme 788.25
820.61
1 month
730.34
Extreme 730.34
820.61
Current year
579.05
Extreme 579.05
820.61
1 year
422.06
Extreme 422.0601
820.61
3 years
196.68
Extreme 196.68
820.61
5 years
101.36
Extreme 101.36
820.61
10 years
58.50
Extreme 58.5
820.61
More quotes
Managers TitleAgeSince
Chief Executive Officer 56 31/12/95
Director of Finance/CFO 51 31/12/00
President - -
Members of the board TitleAgeSince
Director/Board Member 63 24/01/21
Director/Board Member 68 31/03/09
Director/Board Member 63 31/12/04
More insiders
Date Price Change Volume
29/05/24 802.5 -0.66% 168 528
28/05/24 807.9 +0.05% 2,483,454
24/05/24 807.4 -0.13% 1,778,120
23/05/24 808.4 +0.69% 3,025,781
22/05/24 802.9 -0.03% 1,767,519

Delayed Quote Nyse, May 28, 2024 at 09:00 pm

More quotes
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows: - endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems; - oncology (19.5%); - immunology diseases (11.1%); - neurology (8.4%): primarily drugs used in treating depression and schizophrenia; - other (3.3%). Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
807.9 USD
Average target price
850.8 USD
Spread / Average Target
+5.31%
Consensus